Danish Adcendo announces oversubscribed US 135 million Series B Financing to advance ADC pipeline

Mazanti Transactions advised a group of investors on their participation in the US 135 million Series B Financing of Adcendo.

The round was led by California-based investor TCGX, with participation from new investors TPG, Orbimed Advisors, Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), and Logos Capital, as well as all existing investors, including Novo Holdings, RA Capital Management, Pontifax Venture Capital, Dawn Biopharma, HealthCap, Gilde Healthcare, and Ysios Capital.

Founded in 2017 and headquartered in Copenhagen, Adcendo is a Danish biotech company specialising in the development of antibody-drug conjugates (ADCs) for treatment of solid tumors. Adcendo will use the funds to develop and expand its early-stage ADC programs taking aim at cancers with high unmet medical needs.

Mazanti Transactions advised a group of investors on all aspects of the investment in Adcendo with a team led by Lars Lüthjohan.